Associations of Helicobacter pylori infection with NAFLD, MAFLD, MASLD, and Chinese MAFLD.

IF 3.8 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Therapeutic Advances in Gastroenterology Pub Date : 2026-07-31 eCollection Date: 2026-01-01 DOI:10.1177/17562848261465720

Honglu Yu, Yuting Gao, Xiaomin Wang, Lan Chen, Yongguo Zhang, Hongyu Li, Nahum Méndez-Sánchez, Xingshun Qi

{"title":"Associations of Helicobacter pylori infection with NAFLD, MAFLD, MASLD, and Chinese MAFLD.","authors":"Honglu Yu, Yuting Gao, Xiaomin Wang, Lan Chen, Yongguo Zhang, Hongyu Li, Nahum Méndez-Sánchez, Xingshun Qi","doi":"10.1177/17562848261465720","DOIUrl":null,"url":null,"abstract":"Background: The association of Helicobacter pylori (H. pylori) infection with non-alcoholic fatty liver disease (NAFLD) remains controversial. Additionally, its associations with metabolic dysfunction-associated fatty liver disease (MAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD), and Chinese MAFLD using the most recent diagnostic criteria were unclear.Objective: To analyze the associations of H. pylori infection with NAFLD, MAFLD, MASLD, and Chinese MAFLD.Design: Cross-sectional study.Methods: This study screened 1172 inpatients who underwent both H. pylori test and liver computed tomography or ultrasound examination between June 2020 and May 2024. Multivariate Logistic regression analyses were performed to evaluate the associations of H. pylori infection with the severity of hepatic steatosis and risk of hepatic fibrosis. Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were calculated after adjusting for gender, hypertension, hyperlipidemia, body mass index (BMI), fasting plasma glucose (FPG), and high-sensitivity C-reactive protein (HsCRP) in NAFLD analyses; age, gender, drinking, hypertension, diabetes, hyperlipidemia, BMI, and HsCRP in MAFLD analyses; and gender, drinking, hypertension, hyperlipidemia, BMI, FPG, and HsCRP in MASLD and Chinese MAFLD analyses.Results: Overall, 875, 982, 869, and 869 patients were included in NAFLD, MAFLD, MASLD, and Chinese MAFLD analyses, respectively. In NAFLD, MAFLD, MASLD, and Chinese MAFLD analyses, 257, 302, 257, and 257 patients had H. pylori infection, respectively. H. pylori infection was independently associated with severe hepatic steatosis in NAFLD (aOR = 3.956; 95% CI = 1.171-13.359, p = 0.027), MAFLD (aOR = 3.730; 95% CI = 1.083-12.850, p = 0.037), and MASLD (aOR = 3.962; 95% CI = 1.158-13.557, p = 0.028) analyses, but not Chinese MAFLD analyses. However, H. pylori infection was not independently associated with the risk of hepatic fibrosis.Conclusion: H. pylori infection may increase the severity of NAFLD, MAFLD, and MASLD, but not the risk of liver fibrosis.","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"19 ","pages":"17562848261465720"},"PeriodicalIF":3.8000,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13428119/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848261465720","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The association of Helicobacter pylori (H. pylori) infection with non-alcoholic fatty liver disease (NAFLD) remains controversial. Additionally, its associations with metabolic dysfunction-associated fatty liver disease (MAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD), and Chinese MAFLD using the most recent diagnostic criteria were unclear.

Objective: To analyze the associations of H. pylori infection with NAFLD, MAFLD, MASLD, and Chinese MAFLD.

Design: Cross-sectional study.

Methods: This study screened 1172 inpatients who underwent both H. pylori test and liver computed tomography or ultrasound examination between June 2020 and May 2024. Multivariate Logistic regression analyses were performed to evaluate the associations of H. pylori infection with the severity of hepatic steatosis and risk of hepatic fibrosis. Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were calculated after adjusting for gender, hypertension, hyperlipidemia, body mass index (BMI), fasting plasma glucose (FPG), and high-sensitivity C-reactive protein (HsCRP) in NAFLD analyses; age, gender, drinking, hypertension, diabetes, hyperlipidemia, BMI, and HsCRP in MAFLD analyses; and gender, drinking, hypertension, hyperlipidemia, BMI, FPG, and HsCRP in MASLD and Chinese MAFLD analyses.

Results: Overall, 875, 982, 869, and 869 patients were included in NAFLD, MAFLD, MASLD, and Chinese MAFLD analyses, respectively. In NAFLD, MAFLD, MASLD, and Chinese MAFLD analyses, 257, 302, 257, and 257 patients had H. pylori infection, respectively. H. pylori infection was independently associated with severe hepatic steatosis in NAFLD (aOR = 3.956; 95% CI = 1.171-13.359, p = 0.027), MAFLD (aOR = 3.730; 95% CI = 1.083-12.850, p = 0.037), and MASLD (aOR = 3.962; 95% CI = 1.158-13.557, p = 0.028) analyses, but not Chinese MAFLD analyses. However, H. pylori infection was not independently associated with the risk of hepatic fibrosis.

Conclusion: H. pylori infection may increase the severity of NAFLD, MAFLD, and MASLD, but not the risk of liver fibrosis.

查看原文本刊更多论文

幽门螺杆菌感染与NAFLD、MAFLD、MASLD和中国人MAFLD的关系。

背景：幽门螺杆菌（H. pylori）感染与非酒精性脂肪性肝病（NAFLD）的关系仍有争议。此外，其与代谢功能障碍相关脂肪性肝病（MAFLD）、代谢功能障碍相关脂肪性肝病（MASLD）以及使用最新诊断标准的中国MAFLD的相关性尚不清楚。目的：分析幽门螺杆菌感染与NAFLD、MAFLD、MASLD和中国人MAFLD的关系。设计：横断面研究。方法：本研究筛选了2020年6月至2024年5月期间接受幽门螺杆菌检查和肝脏计算机断层扫描或超声检查的1172例住院患者。采用多变量Logistic回归分析来评估幽门螺杆菌感染与肝脂肪变性严重程度和肝纤维化风险的关系。在NAFLD分析中对性别、高血压、高脂血症、体重指数（BMI）、空腹血糖（FPG）和高敏c反应蛋白（HsCRP）进行校正后，计算校正优势比（aORs）和95%置信区间（CIs）；MAFLD分析中的年龄、性别、饮酒、高血压、糖尿病、高脂血症、BMI和HsCRP；以及性别、饮酒、高血压、高脂血症、BMI、FPG和HsCRP在MASLD和Chinese MAFLD分析中的影响。结果：总体而言，NAFLD、MAFLD、MASLD和中国MAFLD分析分别纳入了875、982、869和869例患者。在NAFLD、MAFLD、MASLD和中国MAFLD分析中，分别有257例、302例、257例和257例患者存在幽门螺杆菌感染。在NAFLD （aOR = 3.956; 95% CI = 1.171-13.359, p = 0.027）、MAFLD （aOR = 3.730; 95% CI = 1.083-12.850, p = 0.037）和MASLD （aOR = 3.962; 95% CI = 1.158-13.557, p = 0.028）分析中，幽门螺杆菌感染与严重肝脂肪变性独立相关，但与中国MAFLD分析无关。然而，幽门螺杆菌感染与肝纤维化风险并无独立相关性。结论：幽门螺杆菌感染可增加NAFLD、MAFLD和MASLD的严重程度，但不增加肝纤维化的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.70

自引率

2.40%

发文量

103

审稿时长

15 weeks

期刊介绍： Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of gastroenterology and hepatology. The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.